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The unusual tolerogenicity ascribed to liver has been invariably attributed to its greater load of 
bone marrow-derived cells (1), which after transplantation migrate into the recipient, and play 
an important role in the induction and subsequent maintenance of donor-specific tolerance (1, 
2). Since persistence of donor cell chimerism might confer an advantage to the recipient, a 
natural extension would be to augment this by infusing donor bone marrow at the time of organ 
transplantation. 
In line with this argument, we infused donor bone marrow cells into three t.ype I diabetics, who 
received. pancreatic islets along with kidney (n=2) and. iiver (n = 1) allografts. The long-tenn 
goal was to enhance allograft survival and achieve an insulin-free and possibly a drug· free state. 
Patients: Three type I diabetic patients having a mean age of 34 ±4.7 years were transplanted 
with donor bone marrow, pancreatic islets and kidney (n =2) and liver (n = 1) allografts. Each 
patient received 3 x 108 bone marrow cells/kg body weight, which were infused through a 
central intravenous line. after whole organ transplantation but prior to islet infusion. The ABO 
compatible donors had HLA antigen mismatches with the recipients of 6 and 5 for the kidney 
and 3 for the liver. All patients received routine immunosuppression with FK506 and 
prednisone, whereas kidney-islet recipients additionally received Imuran. All episodes of acute 
rejection were treated with a transient increase in their routine immunosuppression. 
Islet Isolation & Transplantation: Human pancreatic islets were obtained by a modification 
of an automated method described previously (3). Shortly after the allografts were 
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revascularized, a dose of 5.7 x 105 - 1.5 x 106 fresh islets (3.2 x 105 - 8.6 x 105 islet 
equivalents) from the organ donor were infused into the portal vein. 
Post-Transplant Monitoring of Islet Function: Islet function was monitored by routine plasma 
glucose and C-peptide levels. A Sustacal challenge test was done at four weeks after 
transplantation, and every three months thereafter, with glycosylated hemaglobin (HbAlc) levels 
being measured every six weeks after transplantation. 
Detection of Chimerism & In Vitro Immune Monitoring: Peripheral blood mononuclear cells 
(PBMC) were used to detect the presence of donor cells and to monitor the in vitro immune 
status of the recipients by techniques listed in Table L and described in detail elsewhere (4). 
RESULTS Al~Da DTSCUSSION 
The infusion of bone marrow and p::mcre:1tlC islets was uneventful and all whole organ 
allografts are functioning well. The plasma C-peptide activity in a liver-islet-bone marrow 
recipient increased from 0.05 pmoles/ml before transplant to 0.83 pmoles/ml at POD 54, falling 
eventually to 0.02 pmoles/ml at POD 131. This precipitous fall was triggered by the 
involvement of the colon with post-transplant lymphoproliferative disorder, which required a 
complete withdraw of immunosuppression resulting in an episode of acute cellular rejection (mild 
to moderate) on POD 86. To achieve normal blood glucose levels, this patient is currently being 
maintained on 29 U/day of insulin. down from 68 U/day, which was required prior to 
transplantation. He is currently receiving 10 mg/day of FK506 and 5 mg/day of steroids, and 
has normal liver function. He is chimeric and remains reactive against the donor in in vitro 
MLR assays for up to the last sample tested (POD 131). 
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One kidney-islet-bone marrow recipient who started with no detectable pre-transplant 
plasma C-peptide activity, exhibited a level of 0.11 pmoles/ml on POD 276 after reaching a 
level of 0.35 pmoles/ml on POD 45. He is 307 days post-transplant and is receiving 30 U/day 
of insulin as compared to 56 units/day prior to islet transplantation. He had one mild acute 
cellular rejection episode on POD 16, and is currently maintained on 26 mg/day of FK506, 2.5 
mg/day of steroids and 75 mg/day of Imuran. The level of chimerism in peripheral blood is 
relatively high (3 %) and he exhibits 42 % reactivity against the donor as compared to that to 
third party on the last date tested (POD 275). 
The other kidney-islet-bone marrow recipient had a circulatory C-peptide activity of 0.56 
pmoles/ml on POD 42, which was elevated from 0.04 pmoles/ml baseline level prior to 
transplantation. Her last C-peptide activity on POD 266 was 0.44 pmoles/ml. She is currently 
being maintained on 36 U/day of insulin while she received - 32 U/day prior to transplantation. 
She is receiving 9 mg/day of FK506, 15 mg/day of steroids and 75 mg/day of Imuran. Despite 
two rejection episodes, she is still chimeric. Furthermore, the donor-specific response in in vitro 
MLR assay on POD 257 was significantly higher as compared to that to third party. 
Combined bone marrow and pancreatic islet-allotransplantation was unable to reverse 
diabetes in all 3 patients. All patients are chimeric and two-thirds (66%) exhibit evolving donor-
specific hypo reactivity . Current C-peptide activity is not high enough to sustain an insulin-free 
existence in two, whereas in the third, a kidney-islet-bone marrow recipient, it may be high 
enough to result in eventual insulin-withdrawal. The causes of poor islet function are unclear 
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and may be attributed to transplantation of a low critical islet cell mass, to rejection or to an 
inappropriate site of islet transplantation. 
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